# Lapiteronel

Source: https://onco.cc/drugs/lapiteronel/  
OnCo record `lapiteronel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lapiteronel is an experimental pill from Laekna Therapeutics, in phase 2 trials for metastatic castration-resistant prostate cancer.

## Summary

Lapiteronel (LAE001) is a small molecule from Laekna Therapeutics. Blocks CYP17A1 and CYP11B2, enzymes that make androgen and aldosterone hormones. Laekna licensed it from Novartis in 2017. Its pipeline lists lapiteronel with afuresertib and prednisone in metastatic castration-resistant prostate cancer as a US phase 3 programme; the registered company trials found are phase 1/2 (NCT04060394, completed, and NCT03843918, terminated). OnCo has no CYP11B2 target record.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Also known as: LAE001
- Tags: pipeline; ctgov-ingest
- Code: LAE001
- Modality: Small molecule
- Mechanism: Blocks CYP17A1 and CYP11B2, enzymes that make androgen and aldosterone hormones.

## Sources

- Laekna research and development: https://www.laekna.com/rd
- ClinicalTrials.gov NCT04060394: https://clinicaltrials.gov/study/NCT04060394
- ClinicalTrials.gov NCT03843918: https://clinicaltrials.gov/study/NCT03843918

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- targets: [CYP17A1 (17-alpha-hydroxylase/17,20-lyase)](https://onco.cc/targets/cyp17a1/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)
- trials: [A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer](https://onco.cc/trials/nct03843918/), [Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC](https://onco.cc/trials/nct04060394/)

---
JSON: https://onco.cc/api/v1/entities/lapiteronel.json